Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment (Q36496069)

14 August 2017

1 reference

title

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment (English)

1 reference

14 August 2017

Cesar A Migliorati

1

1 reference

14 August 2017

Michael A Siegel

series ordinal

2

1 reference

14 August 2017

Linda S Elting

series ordinal

3

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Lancet Oncology Commission

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

508-514

1 reference

Bisphosphonates for treatment and prevention of bone metastases

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphonates for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Future directions in the treatment and prevention of bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Aetiology of bone disease and the role of bisphosphonates in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Fibrous dysplasia. Pathophysiology, evaluation, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

A prospective randomized study for prevention of postrenal transplantation bone loss

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Interventions to prevent bone loss in astronauts during space flight

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Effects of short-term alendronate on bone mineral density in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Discovery, clinical development, and therapeutic uses of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Interfering with bone remodelling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Long-term safety of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Intraosseous circulation from physiology to disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaws associated with cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaw and bisphosphonates

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Exposed bone in oral cavities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970726-4

7 January 2021

10.1016/S1470-2045(06)70726-4

Identifiers

DOI

1 reference

14 August 2017

1 reference